Sermorelin

Molecular formula Ci4gH246N44042S Molecular weight 3357.94 CAS Registry No 86168-78-7 Merck Index 13,8535 

Sample preparation Condition a Sep-Pak C18 SPE cartridge with MeOH, 0.01% trifluoroacetic acid in MeCN, and 0.01% trifluoroacetic acid in water. Mix 200 [iL serum with 800 jrL cold 50 mM pH 0.8 (sic) phosphate buffer, add to the SPE cartridge, elute with 2 mL MeCN water trifluoroacetic acid 40 60 0.01, lyophilize the eluate, reconstitute with initial mobile phase, inject an aliquot. 

Mobile phase Gradient. MeCN water trifluoroacetic acid from 20 80 0.01 to 36 64 0.01 over 40 min, wash at 40 60 0.01 for 10 min. 

Boulanger, L. Roughly, P. Gaudreau, P. Catabolism of rat growth hormone-releasing factor 1-29) amide in rat serum and liver. Peptides, 1992,13, 681-689. 

---

GHRH is not currently available commercially in research use it may be administered intravenously, subcutaneously, or intranasally, and the relative potencies (defined as incremental growth hormone release) by these three routes are 300, 10, and 1, respectively. Intravenous GHRH (1 g/kg) has a distribution half-life of 4 minutes and an elimination half-life of 53 minutes. Subcutaneous GHRH has a similar elimination half-life but a distribution half-life of about 10 minutes. Peak serum levels of GHRH (1 g/kg) are 37 times higher after intravenous administration compared with subcutaneous injection. Sermorelin, 2 g/kg subcutaneously, reaches peak serum concentrations in 5-20 minutes its bioavailability is 6%. The half-life of sermorelin is about 12 minutes after either subcutaneous or intravenous injection. 

Sermorelin may be used as a diagnostic test for pituitary GH reserve according to the following protocol After an overnight fast, the patient has blood drawn for GH at -15 and 0 minutes sermorelin 1 g/kg is injected intravenously, followed by a 3 mL normal saline flush of the infusion line. Blood for GH is then drawn at 15, 30, 45, and 60 minutes following the injection. Serum GH levels must reach a peak of over 2 ng/mL to be considered a positive response. 

Sermorelin is usually given subcutaneously at a dosage of 0.03 mg/kg body weight once daily at bedtime. Alternative regimens include GHRH, 2-5 g/kg subcutaneously every 6-12 hours. GHRP-2 has been administered intranasally in doses of 5-20 ig/kg. Hexarelin has clinical activity in doses of 20 g/kg intranasally. 

Growth hormone releasing hormone (GHRH), sermorelin... 

Geref Sermorelin Growth hormone deficiency Serono Expired (2004)... 

Sermorelin is an analogue of the hypothalamic growth hormone releasing hormone (somatorelin) it is used in a diagnostic test for growth hormone secretion from the pituitary. 

Clinically important, potentially hazardous interactions with acenocoumarol, anagrelide, anticoagulants, bismuth, boswellia, calcium hydroxylapatite, capsicum, cholestyramine, desvenlafaxine, devil s claw, dexamethasone, dexibuprofen, dicumarol, etodolac, evening primrose, flunisolide, ginkgo biloba, ginseng, heparin, ibuprofen, indomethacin, ketoprofen, ketorolac, lumiracoxib, methotrexate, methylprednisolone, nilutamide, NSAIDs, phellodendron, prednisone, resveratrol, reteplase, rivaroxaban, sermorelin, sulfites, tirofiban, triamcinolone, urokinase, valdecoxib, valproic acid, verapamil, warfarin... 

Clinically important, potentially hazardous interactions with aldesleukin, aspirin, diflunisal, diuretics, methotrexate, NSAIDs, prednisolone, prednisone, sermorelin, tiludronate, torsemide, triamterene, urokinase... 

Clinically important, potentially hazardous interactions with alcohol, dimercaprol, ethanolamine, eucalyptus, guanethidine, hydrocortisone, lanreotide, pegvisomant, propranolol, sermorelin, vidarabine, zofenopril... 

Geref sermorelin griseofulvin Fulcin, Fulvina P/G, Grifulvin V, Gris-PEG, Grisefuline,... 

Gerel sermorelin Griseostatin, Grisovin, Likudin M, Polygris... 

Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1 -29 NH2) consisting of 44 amino acid residues. The free base of sermorelin has the empirical formula C 149 H 246 N 44 O 42 S and a MW of 3358 Da. 

Each vial contains 0.5 mg of sermorelin (as the acetate) and 5 mg of mannitol. The pH is adjusted with dibasic sodium phosphate and monobasic sodium phosphate buffer. Each 1.0-mL vial contains 1.0 mg of sermorelin (as the acetate) and 5 mg of mannitol. The pH is adjusted with dibasic sodium phosphate and monobasic sodium phosphate buffer. 

The recommended dose of sermorelin is 0.03 mg/kg administered daily by subcutaneous injection. No serious adverse events have... 

USA sermorelin acetate peptide Geref Recombinant 1-29 residues of human growth hormone-releasing hormone Hormone... 

Sermorelin, a growth-hormone-releasing hormone, is used as a diagnostic aid to determine the pituitary gland s ability to secrete growth hormone. 

In addition to GH, sermorelin acetate (geref), a synthetic form of human GHRH containing residues 1-29, is FDA-approved for diagnostic purposes. Sermorelin used therapeutically (30 /tg/kg/day given subcutaneously) was less effective than GH in clinical trials. This agent will not work in patients whose GH deficiency results from defects in the anterior pituitary. 

---